Dataset Information

Differential N6-methyladenosine(m6A) modification in hypertrophic scar v.s. normal skin

ABSTRACT: N6-methyladenosine (m6A) is the most prevalent internal modification in eukaryotes. Here, m6A-mRNA and lncRNA transcriptomes were profiled for HS and full-thickness normal skin (NS) tissues using human m6A-mRNA and lncRNA epitranscriptomic microarray. These data exhibited 5838 differentially m6A methylated transcripts (4706 mRNAs, 1132 lncRNAs) between HS and NS tissues. Of note, most of them (about 94%) were hypermethylated. And 3197 differentially expressed mRNAs (1466 upregulated and 1731 downregulated) were obtained by microarray. Conjoint analysis of differentially methylated and differentially expressed transcripts screened 815 transcripts (675 hyper-up, 140 hypo-down). Among them, IFNGR1 (ENST00000367739) and IL37 (ENST00000349806) are two of the most significant methylated transcripts in hyper-up and hypo-down groups. This study proposed a transcriptional regulatory network of m6A modifications on mRNA and lncRNA in human hypertrophic scar, which may bring a new clue into the development, pathogenesis, and treatment of abnormal scars.

ORGANISM(S): Homo sapiens

PROVIDER: GSE212035 | GEO | 2025/08/25

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:This research aims at assessing the m6A methylome in the RA peripheral blood mononuclear cells (PBMCs) and perform potential drug targets prediction analysis. Five RA samples and ten control samples were obtained from China-Japan Friendship Hospital. The various expression of m6A methylation and genes in RA and control group were compared with methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq). Bioinformatics explorations were also made to explore the enriched biological roles and paths of the differentially expressed m6A methylation and genes. Potential drug targets prediction and validation were also constructed to provide potential therapeutic targets for RA. In total, 583 dysregulated m6A peaks, of which 295 were greatly upregulated and 288 were greatly downregulated, were identified. Similarly, 1570 differentially genes were acquired by RNA-seq, including 539 upregulated and 1031 downregulated. According to deeper joint exploration, the m6A methylation and mRNA expression degrees of 35 genes varied greatly, of which including 13 hyper-methylated as well as upregulated genes (hyper-up), 12 hyper-methylated and downregulated genes (hyper-down), 5 hypo-methylated as well as upregulated genes (hypo-up), and 5 hypo-methylated and downregulated genes (hypo-down) GO and KEGG explorations showed the enrichment of these distinct genes in “protein transport” “protein binding” and “lysosome”. In addition, the mRNA levels of TUBB2A, IGF2BP3, DYNC1I1 and FOSL1 were increased and consistent with the trend of our sequencing results. While after the treatment of TP and MTX, their mRNA levels were decreased. This research set up the transcriptional map of m6A in RA PBMCs and displayed the hidden association between RNA methylation alternation and associated genes in RA. The outcomes highlight the importance of m6A modification as a gene regulatory system in RA. Furthermore, TUBB2A, IGF2BP3, DYNC1I1 and FOSL1 might be potential therapeutic targets of TP and MTX during RA treatment.

Dataset Information

Differential N6-methyladenosine(m6A) modification in hypertrophic scar v.s. normal skin

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets